Wang Jia, Hu Jinxin, Qin Dan, Han Dan, Hu Jiapeng
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Liaoning Key Laboratory of Research and Application of Animal Models for Environmental and Metabolic Diseases, Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, China.
World Allergy Organ J. 2024 Dec 7;17(12):101008. doi: 10.1016/j.waojou.2024.101008. eCollection 2024 Dec.
Asthma is a global chronic respiratory disease with complex pathogenesis. While current therapies offer some relief, they often fall short in effectively managing symptoms and preventing exacerbations for numerous patients. Thus, understanding its mechanisms and discovering new drug targets remains a pressing need for better treatment.
Using the GEO dataset, we screened differentially expressed genes (DEGs) in asthma patients' blood. Employing Summary Data-based Mendelian Randomization (SMR) and Two-Sample Mendelian Randomization (TSMR), we pinpointed asthma causal genes, causal DNA methylation sites, and methylation sites affecting gene expression, cross validated with at least 2 large-scale GWAS from each source. We utilized colocalization for genetic associations, meta-analysis for data integration, two-step MR for methylation-gene-asthma mediation mechanism. Druggability was evaluated using Open Target, virtual screening, and docking.
Among the 954 DEGs found in asthma patients' blood, increased expression of CEP95 (discovery, OR_SMR = 0.94, 95% CI: 0.91-0.97), RBM6 (discovery, OR_SMR = 0.97, 95% CI: 0.95-0.99), and ITPKB (discovery, OR_SMR = 0.82, 95% CI: 0.74-0.92) in the blood decreased the risk of asthma, higher levels of HOXB-AS1 (discovery, OR_SMR = 1.05, 95% CI: 1.03-1.07), ETS1 (discovery, OR_SMR = 1.62, 95% CI: 1.29-2.04), and JAK2 (discovery, OR_SMR = 1.13, 95% CI: 1.06-1.21) in the blood increased the risk of asthma. Additionally, a total of 8 methylation sites on ITPKB, ETS1, and JAK2 were identified to influence asthma. An increase in methylation at site cg16265553 raised the risk of asthma partially by suppressing ITPKB expression. Similarly, increased methylation at cg13661497 reduced the asthma risk totally by suppressing JAK2 expression. The impact of CEP95, HOXB-AS1, and RBM6 expressions on asthma was further confirmed in lung tissues. Except for HOXB-AS1, all the other genes were potential druggable targets.
Our study highlighted that specific gene expressions and methylation sites significantly influence asthma risk and revealed a potential methylation-to-gene-to-asthma mechanism. This provided pivotal evidence for future targeted functional studies and the development of preventive and treatment strategies.
哮喘是一种全球范围内的慢性呼吸道疾病,发病机制复杂。虽然目前的治疗方法能提供一定缓解,但对许多患者而言,在有效控制症状和预防病情加重方面往往效果欠佳。因此,了解其发病机制并发现新的药物靶点仍是实现更好治疗效果的迫切需求。
利用基因表达综合数据库(GEO)数据集,我们筛选了哮喘患者血液中的差异表达基因(DEGs)。采用基于汇总数据的孟德尔随机化(SMR)和两样本孟德尔随机化(TSMR)方法,我们确定了哮喘的因果基因、因果DNA甲基化位点以及影响基因表达的甲基化位点,并与来自每个来源的至少2个大规模全基因组关联研究(GWAS)进行交叉验证。我们利用共定位分析基因关联,通过荟萃分析进行数据整合,采用两步孟德尔随机化研究甲基化-基因-哮喘的中介机制。使用开放靶点、虚拟筛选和对接技术评估药物可及性。
在哮喘患者血液中发现的954个差异表达基因中,血液中CEP95(发现阶段,OR_SMR = 0.94,95%置信区间:0.91 - 0.97)、RBM6(发现阶段,OR_SMR = 0.97,95%置信区间:0.95 - 0.99)和ITPKB(发现阶段,OR_SMR = 0.82,95%置信区间:0.74 - 0.92)的表达增加可降低哮喘风险,血液中HOXB - AS1(发现阶段,OR_SMR = 1.05,95%置信区间:1.03 - 1.07)、ETS1(发现阶段,OR_SMR = 1.62,95%置信区间:1.29 - 2.04)和JAK2(发现阶段,OR_SMR = 1.13,95%置信区间:1.06 - 1.21)水平升高会增加哮喘风险。此外,共确定ITPKB、ETS1和JAK2上的8个甲基化位点影响哮喘。位点cg16265553处甲基化增加部分通过抑制ITPKB表达提高哮喘风险。同样,cg13661497处甲基化增加通过抑制JAK2表达完全降低哮喘风险。CEP95、HOXB - AS1和RBM6表达对哮喘的影响在肺组织中得到进一步证实。除HOXB - AS1外,所有其他基因均为潜在的可成药靶点。
我们的研究强调特定基因表达和甲基化位点显著影响哮喘风险,并揭示了一种潜在的甲基化-基因-哮喘机制。这为未来的靶向功能研究以及预防和治疗策略的开发提供了关键证据。